| Bioactivity | ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3]. | ||||||||||||
| Name | ALK4290 | ||||||||||||
| CAS | 1251528-23-0 | ||||||||||||
| Formula | C27H34ClN5O3 | ||||||||||||
| Molar Mass | 512.04 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1. [2]. Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). May-Jun 2020; 9(3):250-259. [3]. Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic |
ALK4290
CAS: 1251528-23-0 F: C27H34ClN5O3 W: 512.04
ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.